Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy IGM Biosciences stock

Own IGM Biosciences stock in just a few minutes.

Posted

Fact checked

IGM Biosciences, Inc is a biotechnology business based in the US. IGM Biosciences shares (IGMS) are listed on the NASDAQ and all prices are listed in US Dollars. IGM Biosciences employs 103 staff and has a market cap (total outstanding shares value) of USD$3 billion.

How to buy shares in IGM Biosciences

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for IGM Biosciences. Find the stock by name or ticker symbol: IGMS. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until IGM Biosciences reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of IGM Biosciences, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of IGM Biosciences. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

IGM Biosciences share price

Use our graph to track the performance of IGMS stocks over time.

IGM Biosciences shares at a glance

Information last updated 2021-02-24.
52-week rangeUSD$27.55 - USD$127.11
50-day moving average USD$96.8606
200-day moving average USD$73.5287
Wall St. target priceUSD$95.3
PE ratio 6.3981
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-71.751

Buy IGM Biosciences shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Robinhood
$0
Stocks, Options, ETFs, Gold/Commodities
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
$0
Stocks, Bonds, Options
$0 + $0.65/contract, $1 minimum
0%
N/A
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Tastyworks
$0
Stocks, Options, Cryptocurrency
Stocks & ETFs: $1/contract to open, $0 to close, $10 max/leg
Futures: $2.50/contract to open, $0 to close
0%
Get 100 shares of stock (worth $1 to $6 a share)
Open and fund a new cash or margin account with $2,000+
Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.
Moomoo
$0 for US stocks
Stocks, Options, ETFs
$0
N/A
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
TradeStation
$0
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$50
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy IGM Biosciences stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Is IGM Biosciences under- or over-valued?

Valuing IGM Biosciences stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of IGM Biosciences's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

IGM Biosciences's P/E ratio

IGM Biosciences's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 6x. In other words, IGM Biosciences shares trade at around 6x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

IGM Biosciences financials

Gross profit TTM USD$-22,649,000
Return on assets TTM -19.33%
Return on equity TTM -32.32%
Profit margin 0%
Book value $8.354
Market capitalisation USD$3 billion

TTM: trailing 12 months

Shorting IGM Biosciences shares

There are currently 2.3 million IGM Biosciences shares held short by investors – that's known as IGM Biosciences's "short interest". This figure is 8.4% down from 2.5 million last month.

There are a few different ways that this level of interest in shorting IGM Biosciences shares can be evaluated.

IGM Biosciences's "short interest ratio" (SIR)

IGM Biosciences's "short interest ratio" (SIR) is the quantity of IGM Biosciences shares currently shorted divided by the average quantity of IGM Biosciences shares traded daily (recently around 188307.4352548). IGM Biosciences's SIR currently stands at 11.97. In other words for every 100,000 IGM Biosciences shares traded daily on the market, roughly 11970 shares are currently held short.

However IGM Biosciences's short interest can also be evaluated against the total number of IGM Biosciences shares, or, against the total number of tradable IGM Biosciences shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case IGM Biosciences's short interest could be expressed as 0.07% of the outstanding shares (for every 100,000 IGM Biosciences shares in existence, roughly 70 shares are currently held short) or 0.2691% of the tradable shares (for every 100,000 tradable IGM Biosciences shares, roughly 269 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against IGM Biosciences.

Find out more about how you can short IGM Biosciences stock.

IGM Biosciences share dividends

We're not expecting IGM Biosciences to pay a dividend over the next 12 months.

IGM Biosciences overview

IGM Biosciences, Inc., a biotechnology company, engages in the research and development of Immunoglobulin M (IgM) antibodies for the treatment of cancer. The company's lead product candidate is IGM-2323, a bispecific IgM antibody that is in Phase 1 clinical trials to treat patients with B cell NHL and other B cell malignancies. It is also developing IGM-8444, an IgM antibody targeting Death Receptor 5 proteins; and IGM-7354, is a bispecific IgM antibody delivering interleukin-15 cytokines to PD-L1 expressing cells for use in the treatment of patients with solid and hematologic malignancies. IGM Biosciences, Inc. has a collaboration with Atreca Inc. and BeiGene Ltd. to discover, develop, and manufacture novel IgM and IgA antibodies targeting SARS-CoV-2 for the potential treatment of COVID-19; and strategic research collaboration and license agreement with AbCellera to discover and develop IgM antibodies. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site